Atomo Diagnostics
- Short interest
- 0.26%
- +0.24 pp 30d
- as of 7 Aug 2023
- Reported shorts
- 1.6M
- Shares on issue
- 605.869M
Atomo Diagnostics (AT1) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $5.2Mvs $3.2M (FY25)
- Yahoo Finance, as at 2 Oct 2026
- NPAT
- −$3.5Mvs −$5.0M (FY25)
- Yahoo Finance, as at 2 Oct 2026
- EPS (diluted)
- −$0.004T (source: Derived: trailing 12 months at year end)vs −$0.008 (FY25)
- Derived: trailing 12 months at year end, as at 2 Oct 2026
- Rev YoY
- +60.9%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Summary of 2026 Appendix 4E and Annual Report, 31 Aug 2026
Atomo Diagnostics reported revenue of $5.33 million for FY2026, up 41% from the prior year, while its net loss narrowed 29% to $3.51 million. No dividend was declared. The company expects continued growth in HIV self-testing and point-of-care cassette supply, particularly in the US market, and aims to improve operating margins by bringing manufacturing in-house.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- 33.9%
- Operating margin
- −110.8%
- Net margin
- −67.2%
- FCF margin
- −65.1%
- ROE
- −47.9%
- ROA
- −35.0%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $3.7M
- Net debt / EBITDA
- n/a
- Current ratio
- 3.0×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $15.3M
- P/E
- n/a
- P/B
- 2.0×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 2 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $5.2M | $3.2M | $4.1M | $2.5M |
| Gross profit | $1.8M | $1.4M | $1.6M | $667.5K |
| Operating income | −$5.8M | −$7.0M | −$7.2M | −$11.2M |
| EBITDA | −$4.4M | −$3.4M | −$5.5M | −$9.3M |
| EBIT | −$5.8M | −$5.0M | −$7.2M | −$11.2M |
| Interest expense | n/a | $6.4K | n/a | n/a |
| Pretax income | −$3.5M | −$5.0M | −$6.8M | −$10.0M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$3.5M | −$5.0M | −$6.8M | −$10.0M |
| Net interest income | $60.4K | $42.2K | $142.6K | $59.1K |
| EPS basic | −$0.004T (source: Derived: trailing 12 months at year end) | −$0.008 | −$0.011 | −$0.017 |
| EPS diluted | −$0.004T (source: Derived: trailing 12 months at year end) | −$0.008 | −$0.011 | −$0.017 |
| Shares | 902.4M | 739.1M | 639.2M | 570.9M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- 2026 Appendix 4E and Annual ReportAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report ended 31 Dec 2025Half Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Oct 2025via asx_announcements
- 2025 Appendix 4E and Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report24 Apr 2025via asx_announcements
- Appendix 4D and Half Year Report ended 31 Dec 2024Half Year Results28 Feb 2025via asx_announcements
Showing 10 of 17 reports